Company Profile
Deciphera Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- DCPH
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for DCPH.
Company overview
Business overview
Deciphera Pharmaceuticals is an oncology company that has focused on kinase biology and targeted cancer therapies. The company’s commercial and pipeline efforts are rooted in precision oncology.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Deciphera sits in specialty oncology biotechnology.
Business Model Characteristics
Its model depends on commercial execution, clinical development, and the ability to extend its targeted-therapy franchise.
Position Within the Biotechnology Landscape
Deciphera is a focused oncology biotech whose valuation is driven by launch performance and pipeline milestones.
Future catalysts
Deciphera's catalysts are QINLOCK, vimseltinib, and any remaining value-realization update that clarifies what is left to drive the story after the transaction backdrop. The next step matters because the stock is really about how much of the old standalone oncology story still has value.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Deciphera Pharmaceuticals do?
Deciphera Pharmaceuticals is an oncology company that has focused on kinase biology and targeted cancer therapies. The company’s commercial and pipeline efforts are rooted in precision oncology.
On which exchange is DCPH stock listed?
Deciphera Pharmaceuticals (DCPH) is associated with NASDAQ, United States, Biopharma.
What is vimseltinib?
Deciphera's catalysts are QINLOCK, vimseltinib, and any remaining value-realization update that clarifies what is left to drive the story after the transaction backdrop.
Which conditions is Deciphera Pharmaceuticals targeting with vimseltinib?
Deciphera Pharmaceuticals is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Deciphera Pharmaceuticals describe recent progress with vimseltinib?
Deciphera's catalysts are QINLOCK, vimseltinib, and any remaining value-realization update that clarifies what is left to drive the story after the transaction backdrop.
What is Deciphera?
Deciphera Pharmaceuticals is an oncology company that has focused on kinase biology and targeted cancer therapies.
What should investors watch for with Deciphera?
Deciphera's catalysts are QINLOCK, vimseltinib, and any remaining value-realization update that clarifies what is left to drive the story after the transaction backdrop.
What is Pharmaceuticals?
Deciphera Pharmaceuticals is an oncology company that has focused on kinase biology and targeted cancer therapies.